Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis

被引：9

作者：

Verstovsek, Srdan ^{[1
]}

Tefferi, Ayalew ^{[2
]}

Korriblau, Steven ^{[1
]}

Thomas, Deborah ^{[1
]}

Cortes, Jorge ^{[1
]}

Ravandi-Kashani, Farhad ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Kantarjian, Hagop ^{[1
]}

机构：

[1] MD Anderson Canc Ctr, Leukemia Dept, Houston, TX USA

[2] Mayo Clin, Coll Med, Div Hematol, Rochester, MN USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.3543.3543

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3543

引用

页码：1037A / 1037A

页数：1

共 50 条

[41] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
Mascarenhas, J.
Marcellino, B. K.
Lu, M.
Kremyanskaya, M.
Fabris, F.
Sandy, L.
Mehrotra, M.
Houldsworth, J.
Najfeld, V.
El Jamal, S.
Petersen, B.
Moshier, E.
Hoffman, R.
LEUKEMIA RESEARCH, 2020, 88
[42] RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A PHASE 1B DOSE-FINDING STUDY
Vannucchi, A. M.
Heidel, F. H.
Ribrag, V.
Kiladjian, J. J.
Passamonti, F.
Hayat, A.
Conneally, E.
Kindler, T.
Martino, B.
Lipka, D. B.
Acharyya, S.
Gopalakrishna, P.
Loechner, S.
Mu, S.
Harrison, C. N.
HAEMATOLOGICA, 2014, 99 : 129 - 130
[43] RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF)
Vannucchi, Alessandro M.
Guglielmelli, Paola
Gattoni, Elisabetta
Antonioli, Elisabetta
Bogani, Costanza
Tozzi, Lorenzo
Pieri, Lisa
Bosi, Alberto
Rambaldi, Alessandro
Barbui, Tiziano
Barosi, Giovanni
BLOOD, 2009, 114 (22) : 130 - 130
[44] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
Xin Du
Daobin Zhou
Frontiers of Medicine, 2016, 10 : 437 - 443
[45] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
Xin Du
Daobin Zhou
Frontiers of Medicine, 2016, 10 (04) : 437 - 443
[46] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
Du, Xin
Zhou, Daobin
FRONTIERS OF MEDICINE, 2016, 10 (04) : 437 - 443
[47] Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
Verstovsek, Srdan
Mesa, Ruben A.
Rhoades, Susanne Kloeker
Giles, Jennifer L. K.
Pitou, Celine
Jones, Emma
Walgren, Richard A.
Prchal, Josef T.
BLOOD, 2011, 118 (21) : 1213 - 1214
[48] THE SELECTIVE JANUS KINASE (JAK) INHIBITOR, INCB018424, SHOWS EFFICACY IN A PHASE I/II TRIAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)
Verstovsek, S.
Kantarjian, H.
Pardanani, A.
Thomas, D.
Cortes, J.
Mesa, R.
Hogan, W.
Redman, J.
Levy, R.
Vaddi, K.
Fridman, J.
Tefferi, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 179 - 179
[49] A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
Andersen, Christen L.
Mortensen, Nana B.
Klausen, Tobias W.
Vestergaard, Hanne
Bjerrum, Ole W.
Hasselbalch, Hans C.
HAEMATOLOGICA, 2014, 99 (01)
[50] Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
A Tefferi
L Saeed
C A Hanson
R P Ketterling
A Pardanani
N Gangat
Leukemia, 2017, 31 : 2851 - 2852

← 1 2 3 4 5 →